Amgen

Open: 238.08 Close: 235.97 Change: -2.11

You'll be sorry if you don't use an AI to decide whether to invest in Amgen.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, investor, lawsuit, AMGN, Amgens, Inc, class, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen (NASDAQ:AMGN) Upcoming Dividend Will be Larger Than Last Years. Amgen looks like a great income stock, and it is only getting better by paying a higher dividend this year. The company has impressed us by growing EPS at 35% per year.

Today's News

Amgen (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Years. Amgen looks like a great income stock, and it is only getting better by paying a higher dividend this year. The company has impressed us by growing EPS at 35% per year over the past five years. Amgen stock (NASDAQ: AMGN) has seen an 8% rise this year, far better than the broader S&P500 index, which is down 18%. Amgens obesity drug, AMG 133, completed a successful phase I trial, which helped lift the companies stock price. Amgen Inc. reports Q1 adjusted EPS $3.98, consensus $3.98, revenue of $6.84 billion and net profit of $1.62 billion. RBC Capital Keeps Their Hold Rating on Amgen (AMGN) TipRanks. Amgen (AMGN) came out with quarterly earnings of $3.98 per share, beating the Zacks Consensus Estimate of $ 3.84 per share. Amgen (AMGN) will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. The Appeal Courts decision upholding the patents for Amgens (AMgen) blockbuster psoriasis drug Otezla will prevent drug-makers from selling a generic version. Janssen filed a BPCIA complaint in the District of Delaware against Amgen related to Amgens ustekinumb biosimilar ABP 654 of Janssens STELARA. Jansens filed a complaint on November 29, 2022, regarding Amgens usteksinumab. Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised Zacks - Friday April 28, 10:52AM CDT Amgen beats estimates for earnings but misses the same for sales. Levi & Korsinsky, LLP notifies investors in Amgen Inc. of a class action securities lawsuit. Lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by alleged securities fraud. Amgen expects full-year earnings in the range of $17.60 to $18.70 per share. Levi & Korsinsky, LLP notifies investors in Amgen Inc. of a class action securities lawsuit. The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by alleged securities fraud. Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Levi & Korsinsky notifies Amgen inc. investors of a class action lawsuit and upcoming deadline. The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by alleged fraud. Bronstein, Gewirtz & Grossman, LLC notifies Amgen Inc. (amgn) investors of class action and to actively participate. U.S. government claimed Amgen owed more than $3 billion in back taxes. Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Amgens product sales grew by 2% in the first quarter, with 14% volume growth weighed down by lower prices (5% impact), lower wholesaler inventories, and foreign exchange.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, investor, lawsuit, AMGN, Amgens, Inc, class, and the most common words in the summary are: amgen, inc, stock, amgn, market, price, news, . One of the sentences in the summary was: Amgen (NASDAQ:AMGN) Upcoming Dividend Will be Larger Than Last Years. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #inc #stock #amgn #market #price #news.